Deep Vein ThrombosisNCT02108041
Personalized Medicine Decision-Making in a Virtual Clinical Setting
An observational study of Deep Vein Thrombosis and Blood Clots, run by National Human Genome Research Institute (NHGRI) at 5 sites in United States.
Trial summary
Background: -How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Deep Vein Thrombosis, Blood Clots
- How many people
- 196 participants
- Where
- 5 sitesUnited States
- Study dates
- Start not givento 8 Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Internal medicine and family medicine residents will be recruited from diverse national sites for the study, and the virtual reality environment will be brought to them through the use of a head-mounted display and laptop
Who may be able to join
- All physicians will be healthy adult volunteers who are medical residents in the internal medicine specialty.
Who cannot join
- persons with seizure or vestibular disorders;
- persons who are highly prone to motion sickness;
- those without normal or normal to corrected vision or hearing;
- all current and past employees and contractors of NHGRI; and
- persons who have received information about the study purpose or procedure from a past participant.
- NHGRI employees are excluded for this protocol because they are likely to have specialized genomic knowledge and may think differently about genomics in the clinical interaction.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
Johns Hopkins School of Medicine
Baltimore, Maryland, 21205
Harvard School of Public Health
Boston, Massachusetts, 02115
University of Oregon
Eugene, Oregon
Michigan State University
Flint, Michigan
Columbia University
New York, New York, 10032-3784
About this study
Official title: Medical Decision-Making in a Virtual Clinical Setting
Background:
-How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice.
Read more
Objective:
-To study how physicians make personalized treatment decisions
Eligibility:
-Healthy adult primary care physicians who are internal (or family) medicine residents.
Design:
- Participants will complete a screening form.
- Participants will put on a headset, called a head-mounted display, showing a virtual reality environment.
- The environment will contain an exam room and the virtual patient.
- After interacting with the virtual patient, participants will complete a series of survey measures.
- Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.
Read the detailed description
This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed.
- Conditions
- Deep Vein Thrombosis, Blood Clots
- Keywords
- Physicians, Genomics, Internal Medicine, Warfarin, Natural History
- Medical subject headings
- Venous Thrombosis, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Physicians that interact with the black/High SES avatar patien | Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American. | |
| Physicians that interact with the black/Low SES avatar patient | Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American. | |
| Physicians that interact with the white race/high SES avatar | Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian. | |
| Physicians that interact with the white race/low SES avatar p | Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial/ethnic and SES backgrounds
To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial /ethnic and SES backgrounds
Measured: Outcome measurements are assessed on the same date of the study visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2014 (estimated)
- Primary completion8 Oct 2020
- Study completion8 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Deep Vein ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 196 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Susan J Persky, Ph.D., Principal investigator, National Human Genome Research Institute (NHGRI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02108041
- Sponsor's protocol ID
- 999914075
- Other IDs
- 14-HG-N075
- Status last verified
- 6 Oct 2026
- First submitted
- 5 Apr 2014
- Last updated
- 29 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We will provide data contingent on special requests form other researchers.
Publications
Green AR, Carney DR, Pallin DJ, Ngo LH, Raymond KL, Iezzoni LI, Banaji MR. Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med. 2007 Sep;22(9):1231-8. doi: 10.1007/s11606-007-0258-5. Epub 2007 Jun 27.
PubMed 17594129Armstrong K. Genomics and health care disparities: the role of statistical discrimination. JAMA. 2012 Nov 21;308(19):1979-80. doi: 10.1001/2012.jama.10820. No abstract available.
PubMed 23138130
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Medical Decision-Making in a Virtual Clinical Setting
- ClinicalTrials.gov ID
- NCT02108041
- Acronym / sponsor ID
- 999914075
- Conditions
- Deep Vein Thrombosis, Blood Clots
- Keywords
- Physicians, Genomics, Internal Medicine, Warfarin, Natural History
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 196 participants (actual)
- Lead sponsor
- National Human Genome Research Institute (NHGRI)US National Institutes of Health
- Primary completion
- 8 Oct 2020 (actual)
- Study completion
- 8 Oct 2020 (actual)
- First posted
- 9 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
-How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice.
Objective:
-To study how physicians make personalized treatment decisions
Eligibility:
-Healthy adult primary care physicians who are internal (or family) medicine residents.
Design:
- Participants will complete a screening form.
- Participants will put on a headset, called a head-mounted display, showing a virtual reality environment.
- The environment will contain an exam room and the virtual patient.
- After interacting with the virtual patient, participants will complete a series of survey measures.
- Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.
Detailed description
This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Physicians that interact with the black/High SES avatar patien | – | –Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American. |
| Physicians that interact with the black/Low SES avatar patient | – | –Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American. |
| Physicians that interact with the white race/high SES avatar | – | –Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian. |
| Physicians that interact with the white race/low SES avatar p | – | –Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Internal medicine and family medicine residents will be recruited from diverse national sites for the study, and the virtual reality environment will be brought to them through the use of a head-mounted display and laptop
Key inclusion criteria (1 listed)
- All physicians will be healthy adult volunteers who are medical residents in the internal medicine specialty.
Key exclusion criteria (6 listed)
- persons with seizure or vestibular disorders;
- persons who are highly prone to motion sickness;
- those without normal or normal to corrected vision or hearing;
- all current and past employees and contractors of NHGRI; and
- persons who have received information about the study purpose or procedure from a past participant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial/ethnic and SES backgrounds
Time frame: Outcome measurements are assessed on the same date of the study visit.
To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial /ethnic and SES backgrounds
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Background: PubMed 17594129Green AR, Carney DR, Pallin DJ, Ngo LH, Raymond KL, Iezzoni LI, Banaji MR. Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med. 2007 Sep;22(9):1231-8. doi: 10.1007/s11606-007-0258-5. Epub 2007 Jun 27.
- Background: PubMed 23138130Armstrong K. Genomics and health care disparities: the role of statistical discrimination. JAMA. 2012 Nov 21;308(19):1979-80. doi: 10.1001/2012.jama.10820. No abstract available.
- Individual participant dataSharing planned: No. We will provide data contingent on special requests form other researchers.
Related trials for Deep Vein Thrombosis
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
Venous Thromboses, Venous Disease
Enrolling by invitationObservational study
ClotTriever® Thrombectomy System Use-Result Survey in Japan
Deep Vein Thrombosis
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
Not yet recruiting
SAFELY RULING OUT DEEP VEIN THROMBOSIS IN PREGNANCY WITH THE LEFt SCORE AND TRIMESTER-ADJUSTED D-DIMER CUTOFFS (the PREG-DVT Study): A PROSPECTIVE COHORT STUDY.
Pregnancy Related, Deep Vein Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan J Persky, Ph.D. principal investigator
National Human Genome Research Institute (NHGRI)
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Deep Vein Thrombosis and Blood Clots, run by National Human Genome Research Institute (NHGRI) at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial/ethnic and SES backgrounds (time frame: Outcome measurements are assessed on the same date of the study visit.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02108041, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.